The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26

Nuclear Medicine and Biology

Volumn 42, Issue 5, 2015, Pages 446-454

  Varasteh, Zohreh ^a   Mitran, Bogdan ^a   Rosenström, Ulrika ^a   Velikyan, Irina ^a   Rosestedt, Maria ^a   Lindeberg, Gunnar ^a   Sörensen, Jens ^a   Larhed, Mats ^a   Tolmachev, Vladimir ^a   Orlova, Anna ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Bombesin antagonistic analog; DOTA; DOTAGA; Molecular imaging; NODAGA; NOTA

Indexed keywords

BOMBESIN ANTAGONIST; DOTAGA POLYETHYLENEGLYCOL DEXTRO PHENYLALANYLGLUTAMINYLTRYPTOPHYLALANYLVALYLGLYCYLHISTIDYLSTATYLLEUCINAMIDE GA 68; GASTRIN RELEASING PEPTIDE RECEPTOR; NODAGA POLYETHYLENEGLYCOL DEXTRO PHENYLALANYLGLUTAMINYLTRYPTOPHYLALANYLVALYLGLYCYLHISTIDYLSTATYLLEUCINAMIDE GA 68; NOTA POLYETHYLENEGLYCOL DEXTRO PHENYLALANYLGLUTAMINYLTRYPTOPHYLALANYLVALYLGLYCYLHISTIDYLSTATYLLEUCINAMIDE GA 68; RADIOPHARMACEUTICAL AGENT; TETRAXETAN POLYETHYLENEGLYCOL DEXTRO PHENYLALANYLGLUTAMINYLTRYPTOPHYLALANYLVALYLGLYCYLHISTIDYLSTATYLLEUCINAMIDE GA 68; UNCLASSIFIED DRUG; BOMBESIN; BOMBESIN RECEPTOR; CHELATING AGENT; GALLIUM; HETEROCYCLIC COMPOUND; MACROCYCLIC COMPOUND; MACROGOL DERIVATIVE;

ANALYTICAL PARAMETERS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING COMPETITION; BONE TISSUE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG STRUCTURE; DRUG TARGETING; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; ISOTOPE LABELING; LUNG PARENCHYMA; MOLECULAR IMAGING; MOUSE; MUSCLE TISSUE; NONHUMAN; PC 3 CELL LINE; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; SOLID PHASE SYNTHESIS; SURFACE CHARGE; TISSUE SPECIFICITY; TUMOR TO ORGAN RATIO; TUMOR XENOGRAFT; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL TRANSFORMATION; CHEMISTRY; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; BINDING, COMPETITIVE; BIOLOGICAL TRANSPORT; BOMBESIN; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CHELATING AGENTS; FEMALE; GALLIUM RADIOISOTOPES; HETEROCYCLIC COMPOUNDS; HUMANS; ISOTOPE LABELING; MACROCYCLIC COMPOUNDS; MALE; MICE; POLYETHYLENE GLYCOLS; PROSTATIC NEOPLASMS; RECEPTORS, BOMBESIN; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION;

EID: 84926153258     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2014.12.009     Document Type: Article

References (29)

1. Ananias H.J., van den Heuvel M.C., Helfrich W., de Jong I.J. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate 2009, 69:1101-1108.
2. Halmos G., Wittliff J.L., Schally A.V. Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression. Cancer Res 1995, 55:280-287.
3. Gugger M., Reubi J.C. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol 1999, 155:2067-2076.
4. Reubi J.C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003, 24:389-427.
5. Maina T., Nock B., Mather S. Targeting prostate cancer with radiolabelled bombesins. Cancer Imaging 2006, 6:153-157.
6. Varshney R., Hazari P.P., Fernandez P., Schulz J., Allard M., Mishra A.K. Theranostics, gallium-68, and other radionuclides. A pathway to personalized diagnosis and treatment 68Ga-labeled bombesin analogs for receptor mediated imaging. Resent results in cancer research 2013, 194:221-246. Springer, New York. R.P. Baum, F. Rösch (Eds.).
7. Varasteh Z., Velikyan I., Lindeberg G., Sörensen J., Larhed M., Sandström M., et al. Synthesis and characterization of a high-affinity NOTA-conjugated bombesin antagonist for GRPR-targeted tumor imaging. Bioconjug Chem 2013, 24:1144-1153.
8. Varasteh Z., Aberg O., Velikyan I., Lindeberg G., Sörensen J., Larhed M., et al. In vitro and in vivo evaluation of a (18)F-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imaging. PLoS One 2013, 8:e81932.
9. Tolmachev V., Stone-Elander S. Radiolabelled proteins for positron emission tomography: pros and cons of labelling methods. Biochim Biophys Acta 1800, 2010:487-510.
10. Varasteh Z., Rosenström U., Velikyan I., Mitran B., Altai M., Honarvar H., et al. The effect of mini-PEG-based spacer length on binding and pharmacokinetic Properties of a 68Ga-labeled NOTA-conjugated antagonistic analog of bombesin. Molecules 2014, 19:10455-10472.
11. Jamous M., Tamma M.L., Gourni E., Waser B., Reubi J.C., Maecke H.R., et al. PEG spacers of different length influence the biological profile of bombesin-based radiolabeled antagonists. Nucl Med Biol 2014, 41:464-470.
12. Harris W.R., Pecoraro V.L. Thermodynamic binding constants for gallium transferrin. Biochemistry 1983, 22:292-299.
13. Delgado R., Félix V., Lima L.M., Price D.W. Metal complexes of cyclen and cyclam derivatives useful for medical applications: a discussion based on thermodynamic stability constants and structural data. Dalton Trans 2007, 26:2734-2745.
14. Price E.W., Orvig C. Matching chelators to radiometals for radiopharmaceuticals. Chem Soc Rev 2014, 43:260-290.
15. Lin M., Welch M.J., Lapi S.E. Effects of chelator modifications on (68)Ga-labeled [Tyr (3)]octreotide conjugates. Mol Imaging Biol 2013, 15:606-613.
16. Fani M., Del Pozzo L., Abiraj K., Mansi R., Tamma M.L., Cescato R., et al. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference. J Nucl Med 2011, 52:1110-1118.
17. Shi J., Kim Y.S., Chakraborty S., Zhou Y., Wang F., Liu S. Impact of bifunctional chelators on biological properties of 111In-labeled cyclic peptide RGD dimers. Amino Acids 2011, 41:1059-1070.
18. Dumont R.A., Deininger F., Haubner R., Maecke H.R., Weber W.A., Fani M. Novel (64)Cu- and (68)Ga-labeled RGD conjugates show improved PET imaging of α(ν)β(3) integrin expression and facile radiosynthesis. J Nucl Med 2011, 52:1276-1284.
19. Tolmachev V., Orlova A. Influence of labelling methods on biodistribution and imaging properties of radiolabelled peptides for visualisation of molecular therapeutic targets. Curr Med Chem 2010, 17:2636-2655.
20. Reubi J.C., Erchegyi J., Cescato R., Waser B., Rivier J.E. Switch from antagonist to agonist after addition of a DOTA chelator to a somatostatin analog. Eur J Nucl Med Mol Imaging 2010, 37:1551-1558.
21. Ginj M., Zhang H., Waser B., Cescato R., Wild D., Wang X., et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A 2006, 103:16436-16441.
22. Wadas T.J., Eiblmaier M., Zheleznyak A., Sherman C.D., Ferdani R., Liang K., et al. Preparation and biological evaluation of 64Cu-CB-TE2A-sst2-ANT, a somatostatin antagonist for PET imaging of somatostatin receptor-positive tumors. J Nucl Med 2008, 49:1819-1827.
23. Cescato R., Maina T., Nock B., Nikolopoulou A., Charalambidis D., Piccand V., et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med 2008, 49:318-326.
24. Mansi R., Wang X., Forrer F., Kneifel S., Tamma M.L., Waser B., et al. Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin Cancer Res 2009, 15:5240-5249.
25. Mansi R., Wang X., Forrer F., Waser B., Cescato R., Graham K., et al. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging 2011, 38:97-107.
26. Abiraj K., Mansi R., Tamma M.L., Fani M., Forrer F., Nicolas G., et al. Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors. J Nucl Med 2011, 52:1970-1978.
27. 64Cu-labeled peptides for PET imaging. J Nucl Med 2014, 55:1719-1725.
28. Eisenwiener K.P., Prata M.I., Buschmann I., Zhang H.W., Santos A.C., Wenger S., et al. NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. Bioconjug Chem 2002, 13:530-541.
29. Wadas T.J., Wong E.H., Weisman G.R., Anderson C.J. Coordinating radiometals of copper, gallium, indium, yttrium and zirconium for PET and SPECT imaging of disease. Chem Rev 2010, 110:2858-2902.